| Literature DB >> 29409820 |
Liping Huang1, Birendra Chaurasiya2, Dawei Wu3, Huimin Wang2, Yunai Du2, Jiasheng Tu4, Thomas J Webster5, Chunmeng Sun6.
Abstract
A reversibly disulfide-crosslinked pullulan nanoparticle with folic acid (FA) decoration (FA-Pull-LA CLNPs) was fabricated for dual-targeted and reduction-responsive anti-tumoral liver drug delivery based on the specific affinity of pullulan and FA to overexpress asialoglycoprtein receptors (ASGPR) and folate receptors (FR), respectively. Paclitaxel (PTX)-loaded FA-Pull-LA nanoparticles (NPs) with satisfactory size, polydispersity index (PDI), and zeta potential exhibited much faster PTX release in the presence of 10mM glutathione (GSH) rather than physiological conditions. In vitro cellular assays confirmed the dual targetability and endosomal accumulation of FA-Pull-LA NPs. In SMMC-7721 tumor-bearing mice, FA-Pull-LA-PTX CLNPs showed the strongest anti-tumor efficiency as well as the lowest toxicity among all three groups. Conclusively, the present study implied that reversibly crosslinked FA-Pull-LA NPs with dual-targeting capacity provided a stable and intelligent platform for efficient liver cancer therapy, which should be further studied for a wide range of anti-cancer applications.Entities:
Keywords: Cancer therapy; Dual-targeting; Pullulan nanoparticles; Reduction-sensitive; Reversible disulfide-crosslinking
Mesh:
Substances:
Year: 2018 PMID: 29409820 DOI: 10.1016/j.nano.2018.01.015
Source DB: PubMed Journal: Nanomedicine ISSN: 1549-9634 Impact factor: 5.307